Lloyd N Mitchell

US Patent:

7399753, Jul 15, 2008

Filed:

Sep 9, 2003

Appl. No.:

10/658617

Inventors:

Lloyd G. Mitchell - Bethesda MD, US
Edward Otto - Great Falls VA, US
Carl R. Merril - Bethesda MD, US

Assignee:

Virxsys Corporation - Gaithersburg MD

International Classification:

C12N 5/10
C12N 15/87
C12N 15/63
C12N 15/66
C12N 15/00
A61K 31/711
C12N 15/861

US Classification:

514 44, 435325, 435455, 435 691, 435 911, 435 913

Abstract:

The present invention provides methods and compositions for conferring selective death on cells expressing a specific target precursor messenger RNA (selective target pre-mRNA). The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a target precursor messenger RNA molecule (target pre-mRNA) expressed within a cell and mediate a trans-splicing reaction resulting in the generation of a novel chimeric mRNA molecule (chimeric mRNA) capable of encoding a light producing protein or enzyme. Cell death is further mediated by the presence of a photosensitizer which upon photoactivation produces cytotoxicity.

US Patent:

7901892, Mar 8, 2011

Filed:

Jul 8, 2002

Appl. No.:

10/190795

Inventors:

Paul F. Agris - Raleigh NC, US
Christopher D. J. Pearce - Surrey, GB
Lloyd G. Mitchell - Durham NC, US

Assignee:

North Carolina State University - Raleigh NC

International Classification:

G01N 33/53

US Classification:

435 71, 435 6

Abstract:

This application describes an antibody that specifically binds to a synthetic oligomer (e. g. , an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.

US Patent:

8053232, Nov 8, 2011

Filed:

Jan 21, 2005

Appl. No.:

11/040634

Inventors:

Madaiah Puttaraju - Germantown MD, US
Edward Otto - Reston VA, US
Mariano A. Garcia-Blanco - Durham NC, US
Gerard J. McGarrity - Gaithersburgh MD, US
Gary F. Temple - Washington Grove MD, US
Lloyd G. Mitchell - Bethesda MD, US
Colette Cote - Gaithersburgh MD, US
S. Gary Mansfield - Montgomery Village MD, US

Assignee:

VIRxSYS Corporation - Gaithersburg MD

International Classification:

C12N 5/00
C12N 15/12
C12N 15/63
C12N 15/86

US Classification:

435325, 4353201

Abstract:

The present invention provides methods and compositions for generating novel nucleic acid molecules through targeted spliceosomal mediated RNA trans-splicing. The compositions of the invention include pre-trans-splicing molecules (PTMs) designed to interact with a SERPINA1 target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA). In particular, the PTMs of the present invention include those genetically engineered to interact with SERPINA1 target pre-mRNA so as to result in correction of SERPINA1 genetic defects responsible for AAT deficiency. The PTMs of the invention may also comprise sequences that are processed out of the PTM to yield duplex siRNA molecules directed specifically to mutant SERPIN A1 mRNAs. Such duplexed siRNAs are designed to reduce the accumulation of toxic AAT protein in liver cells. The methods and compositions of the present invention can be used in gene therapy for correction of SERPINA1 disorders such as AAT deficiency.

US Patent:

8076461, Dec 13, 2011

Filed:

Dec 24, 2003

Appl. No.:

10/746430

Inventors:

Christopher D. J. Pearce - Leatherhead, GB
Lloyd G. Mitchell - Bethesda MD, US

Assignee:

Proteome Sciences PLC - Surrey

International Classification:

C07H 21/02
C07H 21/04

US Classification:

53038821, 435 61, 435 71, 536 231

Abstract:

An antibody microarray is described comprising a plurality of antibodies immobilized on a substrate, wherein each antibody specifically binds to a synthetic oligomer (e. g. , an oligonucleotide or oligopeptide) having an organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are disclosed, along with cells for making such antibodies. Methods of making and using such antibody microarrays are also disclosed.

US Patent:

8173377, May 8, 2012

Filed:

Jan 28, 2011

Appl. No.:

13/016409

Inventors:

Paul F. Agris - Raleigh NC, US
Christopher D. J. Pearce - Surrey, GB
Lloyd G. Mitchell - Durham NC, US

Assignee:

North Carolina State University - Raleigh NC

International Classification:

G01N 33/53

US Classification:

435 71, 435 72, 435518

Abstract:

This application describes an antibody that specifically binds to a synthetic oligomer (e. g. , an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.

US Patent:

8323910, Dec 4, 2012

Filed:

Apr 5, 2012

Appl. No.:

13/440613

Inventors:

Paul F. Agris - Raleigh NC, US
Christopher D. J. Pearce - Surrey, GB
Lloyd G. Mitchell - Durham NC, US

Assignee:

North Carolina State University - Raleigh NC

International Classification:

G01N 33/53

US Classification:

435 71, 436518

Abstract:

This application describes an antibody that specifically binds to a synthetic oligomer (e. g. , an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies.

US Patent:

20020193580, Dec 19, 2002

Filed:

Feb 12, 2002

Appl. No.:

10/076248

Inventors:

Lloyd Mitchell - Bethesda MD, US
Mariano Garcia-Blanco - Durham NC, US
Madaiah Puttaraju - Germantown MD, US

International Classification:

C07H021/02
C07H021/04

US Classification:

536/023100

Abstract:

The present invention provides methods and compositions for delivery of synthetic pre-trans-splicing molecules (synthetic PTMs) into a target cell. The compositions of the invention include synthetic pre-trans-splicing molecules (PTMs) with enhanced stability against chemical and enzymatic degradation. The synthetic PTMs are designed to interact with a natural target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA).

US Patent:

20030153054, Aug 14, 2003

Filed:

Feb 12, 2002

Appl. No.:

10/075028

Inventors:

Lloyd Mitchell - Bethesda MD, US
Mariano Garcia-Blanco - Durham NC, US
Madaiah Puttaraju - Germantown MD, US

International Classification:

C12P019/34
C12N005/00

US Classification:

435/091200, 435/375000

Abstract:

The present invention provides methods and compositions for delivery of synthetic pre-trans-splicing molecules (synthetic PTMs) into a target cell. The compositions of the invention include synthetic pre-trans-splicing molecules (PTMs) with enhanced stability against chemical and enzymatic degradation. The synthetic PTMs are designed to interact with a natural target precursor messenger RNA molecule (target pre-mRNA) and mediate a trans-splicing reaction resulting in the generation of a novel chimeric RNA molecule (chimeric RNA).